Maze Therapeutics Inc. reported cash, cash equivalents, and marketable securities of $383.9 million as of September 30, 2025, compared to $196.8 million at December 31, 2024. The company expects its current cash position to fund operations into 2028. No license revenue was recognized for the three and nine months ended September 30, 2025, compared to $2.5 million and $167.5 million, respectively, for the same periods in 2024, mostly due to a $150.0 million upfront payment from a 2024 license agreement with Shionogi & Co., Ltd. Research and development expenses were $25.2 million and $80.9 million for the three and nine months ended September 30, 2025, up from $19.9 million and $61.3 million in the prior year periods, reflecting increased clinical and manufacturing costs and personnel expenses. Key business developments included an oversubscribed private placement in September 2025 raising approximately $150.0 million and the appointment of Misbah Tahir as chief financial officer.